• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肌张力障碍不适量表(DDS):一种新型工具,用于监测肉毒毒素治疗颈肌张力障碍的时间进程。

The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.

机构信息

Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany.

出版信息

Eur J Neurol. 2014 Mar;21(3):459-62. doi: 10.1111/ene.12330. Epub 2014 Jan 16.

DOI:10.1111/ene.12330
PMID:24433495
Abstract

BACKGROUND AND PURPOSE

Conventional scales measure the effect of botulinum toxin (BT) therapy only at specific points in time. The Dystonia Discomfort Scale (DDS), a novel, easy-to-use, self-assessment scale to record temporal profiles of the effect of BT therapy in cervical dystonia (CD), is introduced and evaluated against the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).

METHODS

Seventy-six patients with CD (age 54.4 ± 10.9 years, 34% male) receiving ≤5 cycles of incobotulinumtoxinA (Xeomin); Merz Pharmaceuticals, Frankfurt am Main, Germany) injections at intervals ≥10 weeks used DDS to record the severity of their symptoms daily. DDS data were compared with TWSTRS-Total scores and patients' subjective estimation (SE) of the onset (TO) and waning (TW) of the treatment effect.

RESULTS

The Toronto Western Spasmodic Torticollis Rating Scale - Total scores correlated significantly with DDS (P ≤ 0.028 at all visits evaluated). TO-DDS and TO-SE were 7.9 ± 8.6 and 7.1 ± 4.1 days, respectively; TW-DDS and TW-SE were 41.8 ± 19.2 and 45.1 ± 21.5 days, respectively.

CONCLUSION

The Dystonia Discomfort Scale is a novel, easy-to-use, self-assessment scale for valid and sensitive monitoring of the temporal profile of the effect of BT therapy in patients with CD. DDS provides important additional information about onset, duration, waning, stability and reproducibility of the effects of BT therapy.

摘要

背景与目的

传统量表仅在特定时间点测量肉毒毒素(BT)治疗的效果。Dystonia Discomfort Scale(DDS)是一种新的、易于使用的自我评估量表,用于记录颈肌张力障碍(CD)患者 BT 治疗效果的时间曲线,本文旨在评估其与多伦多西部痉挛性斜颈评定量表(TWSTRS)的相关性。

方法

76 例接受≤5 个周期的依酚氯铵毒素 A(Xeomin;德国法兰克福 Merz 制药公司)注射治疗的 CD 患者(年龄 54.4±10.9 岁,34%为男性),注射间隔≥10 周,使用 DDS 每日记录其症状严重程度。将 DDS 数据与 TWSTRS 总分和患者对治疗效果开始(TO)和消退(TW)的主观估计(SE)进行比较。

结果

多伦多西部痉挛性斜颈评定量表总分与 DDS 显著相关(所有评估访视点 P≤0.028)。TO-DDS 和 TO-SE 分别为 7.9±8.6 和 7.1±4.1 天;TW-DDS 和 TW-SE 分别为 41.8±19.2 和 45.1±21.5 天。

结论

Dystonia Discomfort Scale 是一种新的、易于使用的自我评估量表,用于有效且敏感地监测 CD 患者 BT 治疗效果的时间曲线。DDS 提供了关于 BT 治疗效果的开始、持续时间、消退、稳定性和可重复性的重要补充信息。

相似文献

1
The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.特发性肌张力障碍不适量表(DDS):一种新型工具,用于监测肉毒毒素治疗颈肌张力障碍的时间进程。
Eur J Neurol. 2014 Mar;21(3):459-62. doi: 10.1111/ene.12330. Epub 2014 Jan 16.
2
Botulinum toxin type B for cervical dystonia.用于治疗颈部肌张力障碍的B型肉毒毒素
Cochrane Database Syst Rev. 2005 Jan 25(1):CD004315. doi: 10.1002/14651858.CD004315.pub2.
3
Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.同时使用肉毒毒素 A 治疗颈肌张力障碍和伴随的偏头痛。
Headache. 2012 Sep;52(8):1219-25. doi: 10.1111/j.1526-4610.2012.02164.x. Epub 2012 May 18.
4
Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.初治颈肌张力障碍患者中B型与A型肉毒毒素对比:随机、双盲、非劣效性试验
Mov Disord. 2008 Mar 15;23(4):510-7. doi: 10.1002/mds.21724.
5
Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.经皮穴位电刺激联合康复训练治疗脑卒中后吞咽障碍的疗效观察
J Neurol Neurosurg Psychiatry. 2013 Sep;84(9):1014-9. doi: 10.1136/jnnp-2012-303608. Epub 2013 May 18.
6
Botulinum toxin type B for cervical dystonia.用于治疗颈部肌张力障碍的B型肉毒毒素
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD004315. doi: 10.1002/14651858.CD004315.pub3.
7
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.A型肉毒毒素(丽舒妥)治疗颈肌张力障碍的长期疗效和安全性。
Parkinsonism Relat Disord. 2010 Jun;16(5):316-23. doi: 10.1016/j.parkreldis.2010.03.002. Epub 2010 Mar 31.
8
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.经修饰的重配型肉毒神经毒素 A(NT 201,Xeomin®,A型肉毒神经毒素,不含辅助蛋白)治疗颈肌张力障碍患者的疗效和安全性。
J Neurol Sci. 2011 Sep 15;308(1-2):103-9. doi: 10.1016/j.jns.2011.05.041. Epub 2011 Jul 18.
9
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.按需注射用于治疗眼睑痉挛或颈部肌张力障碍的因可 BotulinumtoxinA(Xeomin®)耐受性良好。
J Neurol Sci. 2014 Nov 15;346(1-2):116-20. doi: 10.1016/j.jns.2014.08.004. Epub 2014 Aug 10.
10
Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data.使用多伦多西部痉挛性斜颈评定量表评分和健康效用评估颈部肌张力障碍的疾病负担:基于患者水平的基线临床试验数据的荟萃分析
J Med Econ. 2014 Nov;17(11):803-9. doi: 10.3111/13696998.2014.953680. Epub 2014 Aug 29.

引用本文的文献

1
Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment.肉毒毒素治疗任务特异性肌张力障碍的长期治疗中的非线性变化。
Toxins (Basel). 2021 May 22;13(6):371. doi: 10.3390/toxins13060371.
2
Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity.抗体导致肉毒毒素治疗失败:使用低抗原性药物重新开始治疗提供了新的治疗机会。
J Neural Transm (Vienna). 2018 Oct;125(10):1481-1486. doi: 10.1007/s00702-018-1911-3. Epub 2018 Jul 31.
3
Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.
肉毒杆菌毒素治疗相关的慢性每日头痛管理实用指南:共识声明
J Neurol. 2015 Oct;262(10):2201-13. doi: 10.1007/s00415-015-7703-x. Epub 2015 Apr 1.